---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-090252"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2023-11-27T23:59:59+00:00"
generated_at: "2026-06-07T21:45:10.055406+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nektar gets Nasdaq bid-price extension to May 2024; stock moves to Capital Market

## Summary
- Nasdaq granted additional 180-day period until May 20, 2024 to regain $1.00 minimum bid price.
- Common stock will transfer from Nasdaq Global Select to Nasdaq Capital Market on Nov 28, 2023.
- Company intends to cure deficiency via reverse stock split if needed before May 20, 2024.
- If compliance not regained, Nasdaq may delist NKTR; company can appeal to a Listing Qualifications panel.
- Stock continues to trade under symbol NKTR on the Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001213900-23-090252
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2023-11-27T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390023090252/0001213900-23-090252-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390023090252/ea189022-8k_nektarther.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-090252
- JSON: https://secwatch.observer/filing/0001213900-23-090252.json
- Plain text: https://secwatch.observer/filing/0001213900-23-090252.txt

## Key facts
- Listing & Compliance Notices
  NEKTAR THERAPEUTICS received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: November 24, 2023, the Company received a written notice (the “Notice”) from Nasdaq stating that the Company is eligible for an additional 180 calendar day period, or until May 20, 2024, to regain compliance with the minimum bid price requirement. In the Notice, Nasdaq noted that the Company’s common stock had not regained compliance with the minimum bid price requirement during the initial 180 calendar day period that ended on November 22, 2023, and that the Company had submitted written notice to Nasdaq of its intention to cure the required minimum bid price deficiency by effecting a reverse
  evidence_url: https://www.sec.gov/Archives/edgar/data/906709/000121390023090252/0001213900-23-090252-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.